CVR number 29154333
Industry 75.0000 Veterinary activities

SALLINGVEJ DYREKLINIK ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  6.8% 4.1% 10.3% 8.3% 6.7%  
Credit score (0-100)  35 47 23 28 36  
Credit rating  BBB BBB BB BB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Gross profit  5,071 5,247 4,658 4,860 5,076  
EBITDA  1,263 1,022 -421 182 451  
EBIT  1,118 846 -598 42.7 328  
Pre-tax profit (PTP)  1,098.3 820.6 -603.8 42.0 329.3  
Net earnings  855.6 640.1 -471.2 32.7 257.1  
Pre-tax profit without non-rec. items  1,098 821 -604 42.0 329  
 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Tangible assets total  675 733 629 396 308  
Shareholders equity total  1,456 1,241 769 802 859  
Interest-bearing liabilities  0.0 0.0 59.7 0.0 0.0  
Balance sheet total (assets)  3,311 2,521 1,551 1,702 1,838  
Net Debt  -1,750 -914 -84.6 -336 -480  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  5,071 5,247 4,658 4,860 5,076  
Gross profit growth  11.5% 3.5% -11.2% 4.3% 4.4%  
Employees  15 11 13 13 13  
Employee growth %  17.2% -25.4% 18.2% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  3,311 2,521 1,551 1,702 1,838  
Balance sheet change%  72.9% -23.9% -38.5% 9.7% 8.0%  
Added value  1,263.0 1,021.6 -421.4 219.6 451.2  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -43 -117 -282 -372 -212  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 -1.0 1.0 2.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  22.0% 16.1% -12.8% 0.9% 6.5%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  43.2% 29.4% -29.4% 2.6% 18.6%  
ROI %  94.3% 61.1% -56.3% 5.1% 37.1%  
ROE %  74.5% 47.5% -46.9% 4.2% 31.0%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  44.0% 49.2% 49.6% 47.1% 46.8%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -138.5% -89.4% 20.1% -184.3% -106.4%  
Gearing %  0.0% 0.0% 7.8% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  22,608.9% 0.0% 18.5% 2.3% 0.0%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  1.1 0.9 0.4 0.8 1.0  
Current Ratio  1.3 1.3 0.9 1.3 1.4  
Cash and cash equivalent  1,749.7 913.8 144.3 336.2 479.9  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  613.7 345.8 -77.4 241.2 376.2  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  86 93 -32 17 35  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  86 93 -32 14 35  
EBIT / employee  76 77 -46 3 25  
Net earnings / employee  58 58 -36 3 20